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Osteoarthritis, characterized by the breakdown of articular cartilage in synovial joints, has long been viewed as the result of 'wear and tear' 1 . Although low-grade inflammation is detected in osteoarthritis, its role is unclear [2] [3] [4] . Here we identify a central role for the inflammatory complement system in the pathogenesis of osteoarthritis. Through proteomic and transcriptomic analyses of synovial fluids and membranes from individuals with osteoarthritis, we find that expression and activation of complement is abnormally high in human osteoarthritic joints. Using mice genetically deficient in complement component 5 (C5), C6 or the complement regulatory protein CD59a, we show that complement, specifically, the membrane attack complex (MAC)-mediated arm of complement, is crucial to the development of arthritis in three different mouse models of osteoarthritis. Pharmacological modulation of complement in wild-type mice confirmed the results obtained with genetically deficient mice. Expression of inflammatory and degradative molecules was lower in chondrocytes from destabilized joints from C5-deficient mice than C5-sufficient mice, and MAC induced production of these molecules in cultured chondrocytes. Further, MAC colocalized with matrix metalloprotease 13 (MMP13) and with activated extracellular signal-regulated kinase (ERK) around chondrocytes in human osteoarthritic cartilage. Our findings indicate that dysregulation of complement in synovial joints has a key role in the pathogenesis of osteoarthritis.
The pathogenesis of osteoarthritis is unclear, and there are currently no treatments that prevent the development of osteoarthritis. Seeking to gain insight into osteoarthritis, we used mass spectrometry to identify proteins aberrantly expressed in the synovial fluid-the fluid that bathes the synovial joints-of individuals with osteoarthritis. We found that proteins of the complement system are differentially expressed in osteoarthritic compared to healthy synovial fluids ( Supplementary Table 1 ). Using less sensitive proteomic techniques, we previously detected 10 of these 12 differentially expressed comple ment proteins in osteoarthritic synovial fluids 5 . The complement system consists of three distinct pathways that converge at the forma tion of the C3 and C5 convertases, which are enzymes that mediate activation of the C5a anaphylatoxin and formation of MAC (com prising the complement effector C5b9) ( Fig. 1a) 6 . Components of the classical (C1s and C4A) and alternative (factor B) pathways, the central components C3 and C5, and the C5, C7 and C9 components of MAC were all aberrantly expressed in synovial fluids from individuals with osteoarthritis ( Fig. 1a and Supplementary Table 1 ).
Validating our proteomic results, an ELISA analysis showed that the concentrations of C3a ( Fig. 1b) and C5b9 ( Fig. 1c) were significantly higher in synovial fluids from individuals with early stage osteoarthritis than in synovial fluids from healthy individuals. Thus, complement activation occurs in synovial joints early in the course of osteoarthritis and persists, albeit at a lower level, during the late phases of osteoarthritis ( Fig. 1c) . Additionally, an immunohis tochemical analysis revealed the presence of MAC in the synovium (data not shown) and around the chondrocytes in cartilage ( Fig. 1d ) from individuals with endstage osteoarthritis, consistent with previ ous findings [7] [8] [9] .
To determine whether the synovium is a source of comple ment components, we analyzed the expression of genes encoding complementrelated proteins (those identified in synovial fluid; Supplementary Table 1 ) in synovial membranes from individuals with osteoarthritis and from healthy individuals. Analysis by unsu pervised hierarchical clustering revealed two major clusters: one cluster containing all the expression profiles from individuals with osteoarthritis (both early and end stage) and one cluster containing all the profiles from healthy individuals ( Fig. 1e and Supplementary  Fig. 1) . Notably, expression of transcripts encoding the comple ment effectors C7, C4A, factor B, C9 and C5 was markedly higher, and expression of transcripts encoding the complement inhibitors clusterin, factor H, C4binding protein and C1 inhibitor was mark edly lower, in osteoarthritic compared to healthy synovial membranes ( Fig. 1e and Supplementary Fig. 1 ). Our results suggest that the syno vial membrane may take on a pathogenic role in osteoarthritis by contributing to excessive complement activation.
To investigate the role of complement in the pathogenesis of osteoarthritis, we used a mouse model of osteoarthritis induced by medial meniscectomy 10 . In humans, tearing of the meniscus often requires meniscectomy, which is a risk factor for knee osteoarthritis 11 . Because the C5 effector is located at the nexus of the complement cascade ( Fig. 1a) , we surgically induced osteoarthritis in C5deficient (C5 − , lacking the ability to secrete the C5 proprotein from cells) 12 and C5sufficient (C5 + ) wildtype mice. Sixteen weeks after surgery, C5 − mice showed substantially less cartilage loss, osteophyte formation and synovitis than C5 + mice ( Fig. 2a,b and Supplementary Fig. 2d ). By contrast, osteoarthritis in this model was not affected by genetic deficiency in C3 (data not shown). The fact that C3 −/− mice were not protected against osteoarthritis can be explained by the observa tion that compensatory mechanisms operate in C3 −/− mice: coagula tion factors compensate for the lack of C3, allowing C5 activation to proceed even in the absence of C3 (ref. 13 ). Corroborating our findings in the C5 − congenic mouse strain, treatment with a neutral izing monoclonal antibody to C5 (ref. 14) attenuated osteoarthritis in wildtype mice ( Fig. 2c) . We also tested the effect of CR2fH, a fusion protein that inhibits activation of C3 and C5 (ref. 15 ), on oste oarthritis. Administration of CR2fH attenuated the development of osteoarthritis in wildtype mice ( Fig. 2d) .
We next determined whether the MACmediated effector arm of the complement cascade is important in osteoarthritis. We found that mice deficient in C6, an integral component of the MAC (Fig. 1a) , were protected against the development of both osteoarthritis and syn ovitis induced by medial meniscectomy (Fig. 2e,f and Supplementary  Fig. 2d ). Conversely, mice deficient in CD59a, an inhibitor of MAC 6 ( Fig. 1a) , developed more severe osteoarthritis and synovitis than their wildtype littermates (Fig. 2g,h and Supplementary Fig. 2a,d) .
Not only meniscectomy but also meniscal tearing can lead to the development of osteoarthritis in humans 11 . We therefore also examined Table 1 ). The scale bar represents the fold change in gene expression compared to the reference control. Complement effectors are shown in red text, and complement inhibitors are shown in blue text. MB, mannose binding; OA, osteoarthritis.
the role of complement in the destabilization of the medial meniscus (DMM) model of osteoarthritis [16] [17] [18] . We found that deficiency in CD59a accentuated the osteoarthritic phenotype in mice subjected to DMM (Fig. 2i,j and Supplementary Fig. 2b-d) . Deficiency in CD59a also accentuated the milder osteoarthritis that developed spontane ously in aged mice (Supplementary Fig. 3) . These findings suggest that MACmediated complement activity has a pathogenic role in osteoarthritis of disparate etiologies.
Resistance to the development of histological osteoarthritis in complementdeficient mice translated to functional benefit. Twelve weeks after medial meniscectomy, C5 − mice had a normal gait, whereas C5 + mice developed an abnormal gait ( Fig. 3) . Timecourse studies revealed that neither C5 + nor C5 − mice had proteoglycan loss or cartilage degeneration at 2 and 4 weeks after medial meniscectomy (Fig. 3b,c) . This period of latency is similar to that observed in the DMM model 16 and in humans who have undergone medial meniscectomy 11 . Eight and 12 weeks after surgery, however, C5 + mice had significant proteoglycan and cartilage loss and synovitis, whereas C5 − mice did not (Fig. 3b,c and Supplementary  Fig. 4) . The osteoarthritic phenotype was pronounced in these mice, probably because of their genetic background and age at the time of surgery, which are both factors that influence the severity of mouse osteoarthritis 16 . Products of dysregulated cartilage remodeling and repair may con tribute to joint inflammation in osteoarthritis [19] [20] [21] [22] . We examined the ability of osteoarthritic cartilage or specific components of the extra cellular matrix (ECM) of cartilage to activate complement in vitro. Pulverized osteoarthritic cartilage induced the formation of C5b9 (MAC), as did the ECM components fibromodulin and aggrecan, but the ECM components type II collagen and matrilin3 did not ( Fig. 4 and Supplementary Fig. 5) . Fibromodulin, which can bind C1q and activate the complement cascade 23 , was present at higher concentrations in osteoarthritic compared to healthy synovial fluid (Fig. 4c) . Other cartilage ECM components, such as cartilage oli gomeric matrix protein, are also present at abnormally high levels in osteoarthritic synovial fluid and can activate complement 19, 20 . Together, these results suggest that the release or exposure of cartilage ECM components may contribute to the pathophysiology of osteoarthritis by activating complement. Our in situ ( Fig. 1d) and in vivo ( Fig. 2e-j and Supplementary  Figs. 2,3 ) findings indicate that MAC is important in mediating complementrelated cartilage damage in osteoarthritis. But how does MAC damage cartilage? Extensive deposition of MAC induces cell lysis and necrotic cell death, whereas sublytic MAC can acti vate signaling pathways that drive the expression of proinflamma tory and catabolic molecules 24 . Because many of the MACencircled chondrocytes in osteoarthritic cartilage seem to be morphologically intact (Figs. 1d, 4h and Supplementary Fig. 6 ), we examined whether MAC induces the expression of proinflammatory and degradative enzymes in osteoarthritis. We first examined the expression of genes encoding these molecules in cultured chondrocytes coated with sub lytic concentrations of MAC. Sublytic MAC increased the chondro cytes' expression of multiple genes implicated in osteoarthritis: genes encoding cartilagedegrading enzymes 17, 18, 22 (MMPs and disin tegrinlike and metallopeptidase with thrombospondin type 1 motif (ADAMTSs)), inflammatory cytokines 25 (chemokine (CC motif) ligand 2 (CCL2), colonystimulating factor 1 (CSF1) and CCL5) and cyclooxygenase 2 (ref. 26) ( Fig. 4d-f ). Sublytic MAC also induced the expression of complement effectors (Fig. 4d) ; chondrocyte pro duction of complement may thus synergize with complement derived from the synovial membrane to amplify pathogenic complement signaling in osteoarthritis.
We next examined the effect of complement deficiency on the in vivo expression of these genes in destabilized mouse joints. Twenty weeks after DMM surgery, chondrocytes from the destabi lized joints of C5deficient mice, which are deficient in MAC and are protected against osteoarthritis (Figs. 2a,b and 3) , expressed lower concentrations of these inflammatory and degradative mediators than did chondrocytes from the destabilized joints of C5sufficient mice (Fig. 4g) . mRNA levels of Jun and Fos, proinflammatory tran scription factors whose expression is induced by MAC 27, 28 , were also lower (Fig. 4g) . In addition, in human osteoarthritic cartilage, MAC colocalized with MMP13 and with activated ERK1 and ERK2 ( Fig. 4h and Supplementary Fig. 6 ), kinases that mediate resistance to MACmediated cell lysis 29 and stimulate the expression of MMP13 by inducing the expression of Fos 30 .
Here we have found that the complement cascade is crucial for the pathogenesis of osteoarthritis. Cartilage ECM components released by or exposed in osteoarthritic cartilage may trigger the comple ment cascade. Additionally, dysregulation of gene expression in joint tissues may contribute to a local preponderance of complement effec tors over inhibitors in osteoarthritis, permitting complement activa tion to proceed unchecked. Complement activation in turn results in the formation of MAC on chondrocytes, which either kills the cells or causes them to produce matrixdegrading enzymes, inflam matory mediators and other complement effectors, all of which promote joint pathology.
Recent findings suggest that lowgrade complement activation contributes to the development of degenerative diseases, such as agerelated macular degeneration 31 and Alzheimer's disease 32 . We propose that osteoarthritis can be added to this list of diseases. Our findings provide a rationale for targeting the complement system as a diseasemodifying therapy for osteoarthritis.
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